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ABSTRACT 
Objectives 
To investigate whether the introduction of performance targets for anticoagulation in atrial 
fibrillation (AF) was associated with a change in use of the ‘resolved atrial fibrillation’ code. 
Design 
Retrospective cohort studies. 
Setting 
Data from The Health Improvement Network (THIN), a UK database of electronic patient records, 
from 2000 to 2016. 
Participants 
250,788 adult patients aged ≥18 years with a diagnosis of AF, including 14,757 with an incident 
diagnosis of ‘resolved AF’. 
Main outcome measures 
Annual and monthly incidence of ‘resolved AF’ from 2000 to 2016. Among patients with ‘resolved 
AF’, for each year we calculated median duration of the preceding AF diagnosis and the proportion 
prescribed anticoagulants prior to ‘resolved AF’. 
Results 
Incidence of ‘resolved AF’ increased from 5.7 to 26.3 per 1000 person-years between 2005 and the 
introduction of AF performance targets in 2006. Compared to the years prior to the introduction of 
the performance targets, incidence has remained higher in every year since their implementation. 
Since 2007, monthly incidence has been highest between January and March. Between 2005 and 
2006, median duration between AF and ‘resolved AF’ diagnoses increased from 276 days (9 months) 
to 1343 days (3 years 8 months). Among ‘resolved AF’ patients with CHA2DS2-VASc score ≥1, 81.9% 
(95%CI 81.1 to 82.6) had no current anticoagulant prescription, and 62.3% (95%CI 61.4 to 63.2) had 
no record of any anticoagulant prescription. 
Conclusion 
The introduction of AF performance targets was followed by a large increase in use of the ‘resolved 
AF’ code, particularly in the months immediately before practices make their anticoagulant 
performance target submissions. Although most AF patients are prescribed anticoagulants, few 
patients diagnosed with ‘resolved AF’ are prescribed anticoagulants and most have never been 
prescribed them. Untreated patients are much more likely to be coded as having ‘resolved AF’.  
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Strengths and limitations of this study 
• Analysis was performed in a large primary care dataset which is generalisable to the UK 
population and included more than a quarter of a million patients with atrial fibrillation (AF). 
• Data was derived from routinely clinical data which is used by general practitioners for 
clinical decision-making. 
• The study explored the potential impact of the introduction of AF into the Quality and 
Outcomes Framework on the use of the ‘resolved AF’ clinical code. 
• Use and interpretation of the ‘resolved AF’ code is likely to vary between general 
practitioners and practices. 
• The primary care dataset contains no direct information on general practitioners’ reasons 
for assigning a ‘resolved AF’ code; possible influencing factors must therefore be inferred 
from explorations of temporal variation, patient diagnostic information and anticoagulant 
prescribing. 
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INTRODUCTION 
Atrial fibrillation (AF) is a common cardiac arrhythmia associated with increased risk of stroke and 
transient ischaemic attack (TIA); this increased risk is attenuated by treatment with 
anticoagulants.1,2,3 AF may be categorised as resolved if normal heart rhythm is restored. However, 
AF may recur after apparent resolution. 4,5 Evidence shows that patients diagnosed as having 
‘resolved AF’ continue to be at increased risk of stroke/TIA; from 2013 to 2016, risk in patients with 
‘resolved AF’ was found to be the same as that in patients with ongoing AF.6 
Factors influencing clinicians to make a diagnosis of ‘resolved AF’ are unclear. Research has 
demonstrated that the prevalence of the AF resolved clinical code in UK general practice increased 
significantly after 2006 and has remained comparatively high since.6 The Quality and Outcomes 
Framework (QOF) is a scheme to improve the clinical quality of care for chronic diseases. General 
practices keep a register of patients with particular chronic diseases and are paid an incentive for 
achieving performance targets for the management of patients on the register. AF was introduced 
into QOF in 2006 with an incentive payment for ensuring that more than a specified percentage of 
patients received drugs for stroke prevention.7 From April 2006, general practices were required to 
maintain a register of patients with AF and to record whether eligible patients were prescribed 
anticoagulants or antiplatelets; patients with a code indicating ‘resolved AF’ are excluded from this 
register. The increase in prevalence of ‘resolved AF’ after 2006 suggests QOF may have contributed 
to the increase in ‘resolved AF’ diagnoses. There was no corresponding jump in the recorded 
prevalence of AF at this time.8 In 2012, the AF QOF indicators were updated to include an 
assessment of stroke risk and to require patients with a high stroke risk to be treated with 
anticoagulants (not antiplatelets).9 
We hypothesised that the introduction of AF into QOF had an impact on the use of the ‘resolved AF’ 
code. The aim of this analysis, therefore, was to use information available in routinely collected 
primary care data to explore this hypothesis by investigating variation in the use of the ‘resolved AF’ 
clinical code over time and across different practices, and to investigate other factors which may 
influence general practitioners to assign a diagnosis of ‘resolved AF’. The specific questions 
addressed were: 
1. What is the annual incidence of ‘resolved AF’ diagnoses and did incidence increase with the 
introduction of AF into QOF? 
2. Since the introduction of AF into QOF, is a diagnosis of ‘resolved AF’ more likely to be 
recorded in the months of January to March, immediately prior to the practice QOF 
submission? 
3. Is there a difference in the duration of AF diagnosis in patients diagnosed as having ‘resolved 
AF’ before and after the introduction of AF into QOF? 
4. Are patients prescribed anticoagulants before their ‘resolved AF’ diagnosis? 
5. How much variation exists between general practices in use of the ‘resolved AF’ code? 
 
Evidence indicating that use of the ‘resolved AF’ code may be influenced by QOF reporting would 
support the recommendation that patients with ‘resolved AF’ be included in QOF AF registers and 
receive ongoing AF management,6 or that the ‘resolved AF’ clinical code be withdrawn. 
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METHODS 
Data source 
Datasets were extracted from The Health Improvement Network (THIN), a database of electronic 
primary care records from UK general practices using Vision software. The version of the database 
from which study datasets were derived included data for approximately 14 million patients at over 
640 practices. THIN comprises coded data on patient demographics, diagnoses, prescriptions issued 
in primary care, consultations and investigations. Data on all prescriptions issued in primary care are 
recorded in THIN; diagnoses that are part of the QOF are well recorded. 
Population 
General practices were eligible for participation from the later of the practice acceptable mortality 
recording (AMR) date,10 Vision installation date plus one year, and the study start date (1 year prior 
to the first index/census date). 
All adult patients aged 18 years and over with a recorded diagnosis of atrial fibrillation and 
registered for at least 365 days before the index/census date were eligible for inclusion. AF was 
defined by a record of a relevant clinical (Read) code. 
Study design 
A retrospective cohort study from 1st January 2000 to 31st December 2016 was carried out. Index 
date was the latest of the following two dates: one year after the patient registered with the 
practice or the date of diagnosis of AF. 
To determine incidence of ‘resolved AF’ among patients with AF, eligible patients were followed up 
from the index date until the earliest of the following: patient left the practice/transferred out, 
death, study end date, most recent data upload from practice, or a diagnosis of ‘resolved AF’. 
Patients with a record of ‘resolved AF’ at study entry were excluded. ‘Resolved AF’ was defined as a 
record of the relevant clinical (Read) code (212R.00 ‘Atrial fibrillation resolved’).6 
To explore temporal variation in AF duration and anticoagulant prescribing preceding a diagnosis of 
‘resolved AF’, a cohort restricted to patients with a diagnosis of ‘resolved AF’ during the study period 
was used. Eligible patients were followed up until the earliest of the following: patient left 
practice/transferred out, death, study end date, most recent data upload from practice, or an 
outcome event. 
To explore practice-level variation in use of the ‘resolved AF’ clinical code, a cross-sectional study 
was carried out on 1st December 2016. 
Analysis 
Annual incidence of ‘resolved AF’ 
Annual incidence rates of a ‘resolved AF’ diagnosis among AF patients were calculated for each year 
from 2000 to 2016 by dividing the number of patients with a new (first) record of ‘resolved AF’ 
(numerator) by the total number of person-years at risk (denominator) for the given year. 
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Monthly variation in use of the ‘resolved AF’ code pre- and post-QOF 
To investigate the impact of QOF on the distribution of ‘resolved AF’ coding throughout the year, 
monthly incidence of ‘resolved AF’ diagnoses (in each month from January to December) was 
calculated in the pre-QOF period (2000 to 2005), in 2006 and 2007, and in the post-QOF period 
(2008 to 2016). Monthly incidence was calculated separately for 2006 and 2007 as annual incidence 
of ‘resolved AF’ in this period, the years of and immediately following the introduction of AF into 
QOF, was found to be substantially higher than in subsequent years. 
In the post-QOF period (2007 onwards), Poisson regression was used to calculate crude and adjusted 
incidence rate ratios of stroke/transient ischaemic attack (TIA) in patients with a ‘resolved AF’ 
diagnosis recorded in January to March compared to April to December, in order to explore any 
possible differences in disease severity between patients coded as resolved at different times of the 
year. The adjusted model included the following covariates: age, sex, CHA2DS2-VASc score 
(categorised as 0, 1 ≥2) and prescription of anticoagulant medication at the time of the ‘resolved AF’ 
diagnosis. 
‘Resolved AF’ cohort 
The following analyses were restricted to patients with a record of ‘resolved AF’. 
Duration of AF diagnosis 
To explore variation over time in duration of AF diagnosis in patients with ‘resolved AF’, median 
(interquartile range, IQR) duration of time between diagnosis of AF (earliest recorded Read code) 
and first record of a ‘resolved AF’ code was calculated for each year in patients with a ‘resolved AF’ 
code. 
Anticoagulant prescribing 
To explore prescribing of anticoagulants to patients with a diagnosis of ‘resolved AF’, the proportion 
of patients on anticoagulant treatment at the time of diagnosis (current treatment, prescribed up to 
90 days prior to ‘resolved AF’ record), 0 to 90 days, and 91 to 180 days after the ‘resolved AF’ 
diagnosis were calculated with 95% CIs for proportions in 1) all ‘resolved AF’ patients and 2) patients 
with a CHA2DS2-VASc score ≥1 (eligible for anticoagulant treatment). The proportion of ‘resolved AF’ 
patients with a CHA2DS2-VASc score ≥1 who had never been prescribed anticoagulants was also 
calculated. Trends over time were explored by calculating the proportions for each year between 
2000 and 2016. 
Cross-sectional analysis 
Practice-level variation in use of ‘resolved AF’ code 
Variation in use of the ‘resolved AF’ code by general practice in 2016 was assessed by plotting the 
percentage of AF patients with any record of a ‘resolved AF’ code (ever) at a given practice against 
the number of AF patients at the practice. Upper and lower control limits (within 3 standard 
deviations of the mean) were calculated. 
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Definitions of variables 
AF, ‘resolved AF’, and stroke/TIA were defined by the presence of a clinical code; the absence of a 
clinical code was taken to indicate no diagnosis. The clinical code lists used have been utilised in a 
number of previous AF studies6,8,11,12,13 and include all codes used in QOF.14 
CHA2DS2-VASc scores were calculated by adding 1 point each for a history of congestive heart failure 
(HF), hypertension, diabetes (DM), vascular disease, age 65-74 years and female sex (if another risk 
factor was present, otherwise 0), and 2 points for age ≥75 and a history of stroke/TIA. HF, 
hypertension, DM and vascular disease were defined by a relevant clinical code. 
Anticoagulants included warfarin, parenteral anticoagulants, other vitamin K antagonists, and 
novel/non-vitamin K oral anticoagulants. 
All statistical analyses were performed in Stata IC version 14.2. 
Patient involvement 
Patients were not involved in the research. 
RESULTS 
Annual incidence of ‘resolved AF’ 
A total of 250,788 patients with AF contributing 1,037,858 person-years were included in the 
analysis; 14,757 patients had an incident diagnosis of ‘resolved AF’. Mean (SD) age was 74.6 (12.1) 
years; 52.6% pf patients were male; median (IQR) follow-up was 3.1 (1.2-6.1) years. 
Incidence of the atrial fibrillation (AF) resolved code in patients with AF showed a sharp rise in 2006 
(Figure 1), at which time AF was introduced into QOF, rising from 5.7 per 1000 person-years in 2005 
to 26.3 per 1000 person-years in 2006. Incidence peaked at 28.6 per 1000 person-years in 2007; it 
declined thereafter, before rising again to 19.5 per 1000 person-years in 2012-13, when further 
changes were made to the QOF AF requirements. Since 2013 the incidence has declined. 
Monthly variation in use of the ‘resolved AF’ code 
Prior to the introduction of AF into QOF (January 2000 to March 2006), incidence of the ‘resolved AF’ 
code remained relatively constant across the 12 months of the year, including the 3 months 
immediately prior to the introduction of AF into QOF (January to March 2006), with monthly 
incidence varying between 3.2 and 7.2 per 1000 person-years (Figure 2). From April 2006 and for the 
subsequent 12 months, incidence of the code steadily increased, reaching a peak of 70.2 per 1000 
person-years in January 2007. From 2007 onwards (post-QOF), incidence of the ‘resolved AF’ code 
has been highest between the months of January and March, the 3 months immediately preceding 
QOF report submission. In the post-QOF period (2008 to 2016) incidence is higher in every month of 
the year relative to the same month in the pre-QOF period. 
From 2007 onwards, 245 patients diagnosed with ‘resolved AF’ in January to March and 358 patients 
diagnosed in April to December had a stroke. Crude incidence rates were 12.4 and 13.8 per 1000 
person-years, respectively. Among patients who received a diagnosis of ‘resolved AF’ after the 
introduction of AF into QOF (2007 onwards), there was no difference in incidence of stroke/TIA in 
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patients who were assigned the code between January and March compared to those given the 
code later in the year: crude IRR 0.90 (95% CI 0.76 to 1.06), adjusted IRR 0.98 (95% CI 0.83 to 1.15). 
‘Resolved AF’ cohort 
14,863 patients with a record of ‘resolved AF’ were included in the cohort from 2000 to 2016. 
Median (IQR) age was 70.7 (59.6-79.6); 58.1% of patients were male. 11,479 (77.2%) patients had a 
CHA2DS2-VASc score ≥1. Median (IQR) follow-up was 3.8 (1.9-6.8) years. 3,384 (22.8%), 1,737 (11.7%) 
and 9,742 (65.5%) patients had a CHA2DS2-VASc score of 0, 1 or ≥2, respectively. 
Duration of time between diagnosis of AF and use of the ‘resolved AF’ code 
Median duration of time between diagnosis of AF and first recording of a ‘resolved AF’ code 
remained between several months and approximately a year (varying from 69 to 335 days) between 
2000 and 2005. In 2006 there was a sharp rise in median duration from 276 days (9 months) in 2005 
to 1343 days (3 years 8 months) in 2006. This indicates that in 2006 more than half of patients who 
were assigned a ‘resolved AF’ code had been diagnosed over 3 ½ years earlier. Median duration then 
declined for several years, before rising again to more than 1000 days in 2012-13. 
Sequence of events in relation to anticoagulant prescribing in ‘resolved AF’ patients 
Few patients were still on anticoagulants when the ‘resolved AF’ code was recorded. In the cohort of 
‘resolved AF’ patients (2000 to 2016), 17.3% (95% CI 16.7 to 17.9) had a current prescription at the 
time of ‘resolved AF’ recording (up to 90 days prior), with 82.7% (95% CI 82.1 to 83.3) not being 
prescribed anticoagulant treatment. There was no correlation between anticoagulant prescribing 
and CHA2DS2-VASc category: 14.6%, 25.6% and 16.8% of patients with scores of 0, 1 and ≥2, 
respectively, were prescribed anticoagulants. This remained true even at high scores: among those 
with CHA2DS2-VASc ≥6, 14.2% were prescribed anticoagulants. Up to 90 days following the ‘resolved 
AF’ diagnosis, 9.8% (95% CI 9.3 to 10.3) of patients were still being prescribed anticoagulants. By 91 
to 180 days after ‘resolved AF’, 8.7% (95% CI 8.3 to 9.2) had a prescription for anticoagulants. 
Among ‘resolved AF’ patients with a CHA2DS2-VASc score ≥1, 18.1% (95% CI 17.4 to 18.9) had a 
current prescription for anticoagulants, while 81.9% (95% CI 81.1 to 82.6) had no current 
prescription. 10.5% (95% CI 10.0 to 11.1) and 9.7% (95% CI 9.2 to 10.3) had prescriptions up to 90 
days and 91 to 180 days following the ‘resolved AF’ diagnosis respectively. The proportion of 
‘resolved AF’ patients prescribed anticoagulants shortly before and after recording of the ‘resolved 
AF’ code varied slightly over time, with a notable drop in 2006 to 9.8% (95% CI 8.5 to 11.4), 
decreasing from 25.2% (95% CI 20.6 to 30.3) in 2005.  
62.3% (95% CI 61.4 to 63.2) of ‘resolved AF’ patients with a CHA2DS2-VASc score ≥1 had no record of 
an anticoagulant prescription. Among the cohort of patients whose first record of AF was after 
registration with the practice (n=13,307), 60.6% (95% CI 59.6 to 61.5) had never been prescribed 
anticoagulants; this proportion varied slightly over time, reaching a peak of 70.2% in 2006 and a low 
of 51.3% in 2016.  
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Practice-level variation 
787 practices with a total of 1,167,771 patients with AF were included in the analysis from 2000 to 
2016. 443 practices with a total of 69,262 patients with AF, of whom 7,261 had a record of ‘resolved 
AF’, were included in the analysis in 2016. 
Variation in use of the ‘resolved AF’ code between general practices 
The proportion of AF patients with a record of ‘resolved AF’ varied between practices, ranging from 
0% to 43% in 2016. The majority of practices fell within the acceptable range (between the upper 
(UCL) and lower (LCL) control limits) based on the size of the practice AF population, although a 
number of practices fell outside this range: 54 (12.2%) practices above the UCL and 30 (6.8%) below 
the LCL (Figure 3). In 2016, 3 practices with more than 100 patients with AF assigned a ‘resolved AF’ 
code to none of these patients, while 10 practices assigned a ‘resolved AF’ code to more than 25% of 
patients with AF. 
Similar patterns in variation were observed in the year immediately after the introduction of AF into 
QOF (2007): the proportion of patients with ‘resolved AF’ ranged from 0% to 40%, with 61 (13.8%) 
practices above the UCL and 30 (6.8%) below the LCL. In 2005, immediately before the introduction 
of AF into QOF, there was slightly less variation: the proportion of patients with ‘resolved AF’ ranged 
from 0% to 30%, with 39 (8.8%) practices above the UCL. None were below the LCL, which was low 
due to the smaller average number of patients with ‘resolved AF’. 
 
DISCUSSION 
Incidence of ‘resolved AF’ rose dramatically in 2006 immediately following the introduction of AF 
into the Quality and Outcomes Framework (QOF).7 Incidence peaked the following year at 28.6 per 
1000 person-years, showing a five-fold increase compared to the incidence prior to QOF; it is 
possible that this increase was in part the result of practices ‘catching up’ with recording ‘resolved 
AF’ following the introduction of QOF. There was a further, smaller, peak in ‘resolved AF’ incidence 
in 2012-13, following a change in the QOF AF indicators to introduce a stroke risk assessment 
indicator and to change the requirements for the anticoagulation indicator.9 A corresponding rise in 
the prevalence of ‘resolved AF’ among patients with AF, from 2.3% in 2005 to 6.4% in 2007 and a 
high of 9.2% in 2013, has been reported previously.6 
Since the introduction of AF into QOF, the majority of ‘resolved AF’ codes have been recorded 
between the months of January and March, immediately prior to QOF report submission by general 
practices. Prior to this, ‘resolved AF’ codes were recorded throughout the year with little monthly 
variation in incidence. There is no difference in stroke/TIA rates in patients diagnosed as having 
‘resolved AF’ between January and March compared to those diagnosed later in the year; patients 
with AF who are diagnosed as resolved immediately prior to QOF do not have a different/lower risk 
of stroke/TIA. 
Immediately following the introduction of AF into QOF, there was a dramatic rise in median duration 
between AF and ‘resolved AF’ diagnoses, with a further peak at the time of changes to QOF in 2012-
13. At these time points, patients designated as having ‘resolved AF’ had been diagnosed with AF 
10 
 
several years previously (median 3 years and 8 months in 2006) compared around one year prior to 
QOF (9 months in 2005). 
Almost two thirds of patients with ‘resolved AF’ and a CHA2DS2-VASc score ≥1 had never been 
prescribed anticoagulants. In 2016, 79.5% of patients with ‘resolved AF’ and a CHA2DS2-VASc score 
≥1 were not prescribed anticoagulants at the time of their ‘resolved AF’ diagnosis, made up of 53.5% 
who had never been prescribed anticoagulants and 26.0% who had previously been prescribed 
anticoagulants but had subsequently discontinued. By contrast, only 25-30% of patients with 
ongoing AF and a CHA2DS2-VASc score ≥1 were not prescribed anticoagulants in 2016.8,15 This 
suggests that patients with AF who are not prescribed anticoagulants may be more likely to be 
assigned a ‘resolved AF’ code. Furthermore, recent evidence indicates that patients with a diagnosis 
of ‘resolved AF’ remain at increased risk of stroke/TIA and may therefore benefit from continued 
anticoagulant prophylaxis.6 The concept of ‘resolved AF’ may be delusive; AF which has apparently 
resolved, even following ablation, may recur.16,17,18 
Use of the ‘resolved AF’ code varies between practices. Some practices with large numbers of AF 
patients use the code for very few patients, while others assign the code to more than a quarter of 
AF patients. 
Strengths and limitations 
This analysis was performed in a large general practice dataset which is generalisable to the UK 
population. Data was derived from routinely clinical data which is used by general practitioners for 
clinical decision-making. The use and interpretation of the ‘resolved AF’ clinical code is likely to vary 
between general practitioners and practices. The primary care dataset contains no direct 
information on general practitioners’ reasons for assigning a ‘resolved AF’ code; possible influencing 
factors have therefore been inferred from explorations of temporal variation, patient diagnostic 
information and anticoagulant prescribing. In order to better understand the factors motivating a 
diagnosis of ‘resolved AF’, a qualitative study and consultation with practicing clinicians would be 
required. 
Anticoagulation rates may be underestimated if treatment is managed entirely in secondary care; 
however, the majority of anticoagulants are prescribed in primary care. AF clinical guidelines and 
stroke risk scoring systems have changed over the study period; for the purpose of this study, we 
used current guidance (eligibility for anticoagulation based on CHA2DS2-VASc score ≥1) across all 
time periods for consistency and comparability. 
Conclusions 
Use of the ‘resolved AF’ code remains common. Most patients eligible for anticoagulant treatment 
who were assigned a ‘resolved AF’ code were never prescribed anticoagulants, and very few patients 
were still taking anticoagulants when the ‘resolved AF’ code was recorded. Those diagnosed as 
having ‘resolved AF’ are no longer included in the AF register for QOF; this has the effect of 
improving the practice’s apparent performance in the QOF. Incidence of the ‘resolved AF’ clinical 
code increased markedly when AF was introduced into QOF in 2006 and increased again when 
further changes were made to the QOF incentive scheme in 2012. Since 2006, incidence of the 
‘resolved AF’ code has been highest in the months shortly before practices make their QOF 
submissions. Previous evidence demonstrated patients with a diagnosis of ‘resolved AF’ remain at 
increased risk of stroke/TIA and are therefore likely to benefit from anticoagulant prophylaxis. We 
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therefore recommend that patients with ‘resolved AF’ should be included when determining 
whether practices meet QOF clinical performance targets. 
 
FIGURES 
 
Figure 1. Annual incidence of resolved atrial fibrillation in patients with AF 2000-2016. 
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Figure 2. Incidence of the ‘resolved AF’ code by month of recording, before, during and after the 
introduction of AF into the Quality and Outcomes Framework (QOF). 
 
Figure 3. Funnel plot showing variation in use of the ‘resolved AF’ code by practice in 2016. 
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